Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody
- PMID: 406347
- PMCID: PMC2180729
- DOI: 10.1084/jem.146.1.201
Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody
Abstract
Cultured mononuclear peripheral blood leukocytes (PBL) from nonimmune human beings and monkeys are nonpermissive to dengue 2 virus (D2V) infection at multiplicities of infection of 0.001-0.1, but become permissive when non-neutralizing dengue antibody is added to medium. D2V infection occurred in PBL prepared from anti-coagulated but not from defibrinated plasma. Infection enhancement was produced by multiple lots of heterotypic anti-dengue raised in several mammalian species. Homotypic anti-dengue neutralized D2V at high concentrations but enhanced at low concentrations; enhancement end point in one serum was 1:320,000. The infection-enhancing factor was a noncytophilic antibody of the IgG class. D2V infection occurred in the absence of heat-labile complement components but did not occur when complexes were prepared with anti- dengue F(ab)(2). Treatment of PBL with several proteases increased permissiveness to D2V infection by immune complexes but not by virus alone. Two rhesus monkey serums collected 14 days after D2V infection contained an IgG antibody with high-titered enhancing activity but with no hemagglutination-inhibition or neutralizing activity. Virus-antibody complexes are irreversibly attached to PBL within 15 min and completely internalized in 60 min. There was considerable variation in cellular infection in different experiments, however, maximum virus yields usually exceeded 1,000 plaque-forming units per 1 x 10(6) PBL occurring between 2 and 4 days in culture. In vitro antibody-dependent infection of PBL provides a possible model for study of pathogenetic mechanisms in infants with dengue shock syndrome who passively acquire maternal anti-dengue IgG.
Similar articles
-
Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.Front Immunol. 2018 Apr 23;9:597. doi: 10.3389/fimmu.2018.00597. eCollection 2018. Front Immunol. 2018. PMID: 29740424 Free PMC article. Review.
-
Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade.Rev Infect Dis. 1989 May-Jun;11 Suppl 4:S830-9. doi: 10.1093/clinids/11.supplement_4.s830. Rev Infect Dis. 1989. PMID: 2665015 Review.
-
Absence of leukocytes permissive to dengue 2 virus in the acute phase of dengue hemorrhagic fever.Am J Trop Med Hyg. 1979 May;28(3):570-6. doi: 10.4269/ajtmh.1979.28.570. Am J Trop Med Hyg. 1979. PMID: 453450
-
Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection.J Exp Med. 1977 Jul 1;146(1):218-29. doi: 10.1084/jem.146.1.218. J Exp Med. 1977. PMID: 195000 Free PMC article.
-
In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.J Infect Dis. 1979 Oct;140(4):527-33. doi: 10.1093/infdis/140.4.527. J Infect Dis. 1979. PMID: 117061
Cited by
-
Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits.Vaccines (Basel). 2024 Apr 9;12(4):396. doi: 10.3390/vaccines12040396. Vaccines (Basel). 2024. PMID: 38675778 Free PMC article. Review.
-
A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.J Virol. 2024 May 14;98(5):e0023924. doi: 10.1128/jvi.00239-24. Epub 2024 Apr 22. J Virol. 2024. PMID: 38647327 Free PMC article.
-
Immunogenicity of chimeric hemagglutinins delivered by an orf virus vector platform against swine influenza virus.Front Immunol. 2024 Feb 28;15:1322879. doi: 10.3389/fimmu.2024.1322879. eCollection 2024. Front Immunol. 2024. PMID: 38482020 Free PMC article.
-
Antibody-mediated SARS-CoV-2 entry in cultured cells.EMBO Rep. 2023 Dec 6;24(12):e57724. doi: 10.15252/embr.202357724. Epub 2023 Nov 2. EMBO Rep. 2023. PMID: 38277394
-
Severe dengue in the intensive care unit.J Intensive Med. 2023 Sep 28;4(1):16-33. doi: 10.1016/j.jointm.2023.07.007. eCollection 2024 Jan. J Intensive Med. 2023. PMID: 38263966 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources